Austar Lifesciences FY26 interim profit attributable to owners drops 66.15% to RMB 8.46 million; revenue rises 12.5% to RMB 744.48 million

• Austar Lifesciences posted 1H 2026 revenue up 12.5% to RMB 744.48 million; profit attributable to owners fell to RMB 8.46 million.
• Basic EPS dropped to RMB 0.02; gross profit margin narrowed 2.4 percentage points to 18.6%.
• Operating cash flow more than doubled to RMB 88.31 million; net cash decreased to RMB 209.7 million at June 30, 2026.
• Order intake declined 19.9% to RMB 834.42 million; IPS fell 21.1% while SIC rose 11.8% on own-brand products.
• Management said it became more selective on projects to target higher margins and better payment terms; interim dividend was nil.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Austar Lifesciences Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260911-12329036), on September 11, 2026, and is solely responsible for the information contained therein.